AD/PD 2022 | Development of a new anti-amyloid antibody PMN310 for the treatment of Alzheimer’s disease

Johanne Kaplan, PhD, ProMIS™ Neurosciences, Inc., Cambridge, MA, gives an update on a new antibody treatment currently in preclinical development, PMN310. PMN310 is a humanized monoclonal antibody which targets misfolded amyloid-beta. There are several amyloid-beta antibodies currently being developed, including aducanumab which was approved in 2021. The advantage of PMN310 compared with its predecessors is that it is only targeted to a conformational epitope present on misfolded amyloid-beta and therefore, does not interfere with the normal monomer forms of amyloid-beta. In addition to this, PMN310 is also designed to not bind plaque, which avoids side-effects such as amyloid‐related imaging abnormalities (ARIA). This interview took place at the AD/PD™ 2022 Conference in Barcelona, Spain.